656 related articles for article (PubMed ID: 9587681)
21. Melanoma: is immunotherapy of benefit?
Faries MB; Morton DL
Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
[No Abstract] [Full Text] [Related]
22. Cell transfer and other immunotherapeutic strategies.
Rosenberg SA
Clin Adv Hematol Oncol; 2005 Jan; 3(1):28-9. PubMed ID: 16166964
[No Abstract] [Full Text] [Related]
23. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
Dillman RO; Beutel LD; Cornforth AN; Nayak SK
Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
[TBL] [Abstract][Full Text] [Related]
24. Does adjuvant vaccine therapy really have activity in malignant melanoma?
Wheatley K; Ives NJ; Lorigan P
J Clin Oncol; 2007 Oct; 25(29):4693; author reply 4693-5. PubMed ID: 17925569
[No Abstract] [Full Text] [Related]
25. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
26. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
27. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
28. Clinical activity of a polyvalent melanoma antigen vaccine.
Bystryn JC
Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
[TBL] [Abstract][Full Text] [Related]
29. Melanoma antigens and targets for vaccination.
Kang N; Truman H; Sanders R; Kupsch J
Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
[TBL] [Abstract][Full Text] [Related]
30. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
31. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
32. Improving the retroviral vector (RV) systems for immunotherapy of cancer.
Grabarczyk P; Gryska K; Wysocki PJ; Izycki D; Mackiewicz A
Adv Exp Med Biol; 2001; 495():389-92. PubMed ID: 11774599
[No Abstract] [Full Text] [Related]
33. [An improved procedure for autologous gene-modified cancer vaccine preparation for active specific immunotherapy of disseminated solid tumors].
Danilov AO; Larin SS; Danilova AB; Moiseenko VM; Baldueva IA; Kiselev SL; Turkevich EA; Barchuk AS; Anisimov VV; Gafton GI; Kochnev VA; Khanson KP
Vopr Onkol; 2004; 50(2):219-27. PubMed ID: 15176227
[TBL] [Abstract][Full Text] [Related]
34. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
35. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy. Neo approaches to cancer vaccines.
Delamarre L; Mellman I; Yadav M
Science; 2015 May; 348(6236):760-1. PubMed ID: 25977539
[No Abstract] [Full Text] [Related]
37. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
38. Melanoma vaccines: breakthrough or bust?
Sabel MS; Sondak VK
Cancer Invest; 2002; 20(7-8):1114-6. PubMed ID: 12449744
[No Abstract] [Full Text] [Related]
39. Immunotherapy of melanoma.
Smith C; Cerundolo V
Immunology; 2001 Sep; 104(1):1-7. PubMed ID: 11576213
[No Abstract] [Full Text] [Related]
40. TroVax(®) vaccine therapy for renal cell carcinoma.
Zhang RT; Bines SD; Ruby C; Kaufman HL
Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
